A Plea for Economically Sustainable Evidence-based Guidelines

A Plea for Economically Sustainable Evidence-based Guidelines

The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness anal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2022-11, Vol.82 (5), p.449-451
Hauptverfasser: Martini, Alberto, Mottet, Nicolas, Montorsi, Francesco, Necchi, Andrea, Ribal, Maria J., Malavaud, Bernard
Format: Artikel
Sprache:eng
Schlagworte:
Cost-Benefit Analysis
Health Care Costs
Humans
Male
Prostatic Neoplasms - therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 451
container_issue 5
container_start_page 449
container_title European urology
container_volume 82
creator Martini, Alberto
Mottet, Nicolas
Montorsi, Francesco
Necchi, Andrea
Ribal, Maria J.
Malavaud, Bernard
description The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.
doi_str_mv 10.1016/j.eururo.2022.08.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2706181502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283822025490</els_id><sourcerecordid>2706181502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-3234c4e654c0561bfb7de8a08d0cc0afd3261bafa0d82c5d859a27934b9afb333</originalsourceid><addsrcrecordid>eNp9kF9LwzAUxYMobk6_gUgffWm9SfonfVAYY05hoKA-hzS5hYyumUk72Le3o9NHnw73cs493B8htxQSCjR_2CTY-967hAFjCYgEgJ6RKRUFj4ssh3MyBQ4sZoKLCbkKYQMAPCv5JZkMUpaUiil5nEfvDaqodj5aate6rdWqaQ7RRx86ZVtVNRgt99ZgqzGuVEATrfphbGyL4Zpc1KoJeHPSGfl6Xn4uXuL12-p1MV_HmuesiznjqU4xz1INWU6ruioMCgXCgNagasPZsFW1AiOYzozISsWKkqdVqeqKcz4j9-PdnXffPYZObm3Q2DSqRdcHyQrIqaAZsMGajlbtXQgea7nzdqv8QVKQR3ByI0dw8ghOgpADuCF2d2roqy2av9AvqcHwNBpw-HNv0cug7RGKsR51J42z_zf8ANIKgIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2706181502</pqid></control><display><type>article</type><title>A Plea for Economically Sustainable Evidence-based Guidelines</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Martini, Alberto ; Mottet, Nicolas ; Montorsi, Francesco ; Necchi, Andrea ; Ribal, Maria J. ; Malavaud, Bernard</creator><creatorcontrib>Martini, Alberto ; Mottet, Nicolas ; Montorsi, Francesco ; Necchi, Andrea ; Ribal, Maria J. ; Malavaud, Bernard</creatorcontrib><description>The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2022.08.001</identifier><identifier>PMID: 35999118</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Cost-Benefit Analysis ; Health Care Costs ; Humans ; Male ; Prostatic Neoplasms - therapy</subject><ispartof>European urology, 2022-11, Vol.82 (5), p.449-451</ispartof><rights>2022 European Association of Urology</rights><rights>Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-3234c4e654c0561bfb7de8a08d0cc0afd3261bafa0d82c5d859a27934b9afb333</citedby><cites>FETCH-LOGICAL-c362t-3234c4e654c0561bfb7de8a08d0cc0afd3261bafa0d82c5d859a27934b9afb333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283822025490$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35999118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martini, Alberto</creatorcontrib><creatorcontrib>Mottet, Nicolas</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Necchi, Andrea</creatorcontrib><creatorcontrib>Ribal, Maria J.</creatorcontrib><creatorcontrib>Malavaud, Bernard</creatorcontrib><title>A Plea for Economically Sustainable Evidence-based Guidelines</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.</description><subject>Cost-Benefit Analysis</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Male</subject><subject>Prostatic Neoplasms - therapy</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF9LwzAUxYMobk6_gUgffWm9SfonfVAYY05hoKA-hzS5hYyumUk72Le3o9NHnw73cs493B8htxQSCjR_2CTY-967hAFjCYgEgJ6RKRUFj4ssh3MyBQ4sZoKLCbkKYQMAPCv5JZkMUpaUiil5nEfvDaqodj5aate6rdWqaQ7RRx86ZVtVNRgt99ZgqzGuVEATrfphbGyL4Zpc1KoJeHPSGfl6Xn4uXuL12-p1MV_HmuesiznjqU4xz1INWU6ruioMCgXCgNagasPZsFW1AiOYzozISsWKkqdVqeqKcz4j9-PdnXffPYZObm3Q2DSqRdcHyQrIqaAZsMGajlbtXQgea7nzdqv8QVKQR3ByI0dw8ghOgpADuCF2d2roqy2av9AvqcHwNBpw-HNv0cug7RGKsR51J42z_zf8ANIKgIQ</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Martini, Alberto</creator><creator>Mottet, Nicolas</creator><creator>Montorsi, Francesco</creator><creator>Necchi, Andrea</creator><creator>Ribal, Maria J.</creator><creator>Malavaud, Bernard</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202211</creationdate><title>A Plea for Economically Sustainable Evidence-based Guidelines</title><author>Martini, Alberto ; Mottet, Nicolas ; Montorsi, Francesco ; Necchi, Andrea ; Ribal, Maria J. ; Malavaud, Bernard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-3234c4e654c0561bfb7de8a08d0cc0afd3261bafa0d82c5d859a27934b9afb333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cost-Benefit Analysis</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Male</topic><topic>Prostatic Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martini, Alberto</creatorcontrib><creatorcontrib>Mottet, Nicolas</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Necchi, Andrea</creatorcontrib><creatorcontrib>Ribal, Maria J.</creatorcontrib><creatorcontrib>Malavaud, Bernard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martini, Alberto</au><au>Mottet, Nicolas</au><au>Montorsi, Francesco</au><au>Necchi, Andrea</au><au>Ribal, Maria J.</au><au>Malavaud, Bernard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Plea for Economically Sustainable Evidence-based Guidelines</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2022-11</date><risdate>2022</risdate><volume>82</volume><issue>5</issue><spage>449</spage><epage>451</epage><pages>449-451</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>35999118</pmid><doi>10.1016/j.eururo.2022.08.001</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2022-11, Vol.82 (5), p.449-451
issn 0302-2838
1873-7560
language eng
recordid cdi_proquest_miscellaneous_2706181502
source MEDLINE; Elsevier ScienceDirect Journals
subjects Cost-Benefit Analysis
Health Care Costs
Humans
Male
Prostatic Neoplasms - therapy
title A Plea for Economically Sustainable Evidence-based Guidelines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T04%3A36%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Plea%20for%20Economically%20Sustainable%20Evidence-based%20Guidelines&rft.jtitle=European%20urology&rft.au=Martini,%20Alberto&rft.date=2022-11&rft.volume=82&rft.issue=5&rft.spage=449&rft.epage=451&rft.pages=449-451&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2022.08.001&rft_dat=%3Cproquest_cross%3E2706181502%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2706181502&rft_id=info:pmid/35999118&rft_els_id=S0302283822025490&rfr_iscdi=true